The combination of the investigational synthetic retinoid fenretinide with selective BCL-2 inhibition was shown to synergistically induce cell death and increase survival in an in vivo model through NOXA upregulation in NB cells that express high levels of BCL-2 [56]. Here, BCL2 is linked to neuroblastoma.